The National Cancer Institute (NCI), Microarray Facility, Advanced Technology Center (ATC) proposes to contract with Operon Technologies, Inc. 1000 Atlantic Avenue, Suite 108, Alameda, CA 94501, for human and mouse genome oligonucleotide sets, catalog numbers GS-500-12 and GS-600-12. The supplies and services herein are commercial as defined in FAR Part 2, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items authorized by FAR Part 13.5. The North American Industry Classification System Code is 422210 and the business size standard is 100 employees. One of the ATC's missions is the manufacturing of quality micro-arrays for comprehensive gene expression analysis, providing training protocols and technical support to NCI researchers and develop new microarray technologies and applications. High density DNA micro-array technology has been used to achieve high throughput analysis of massively parallel genomic sequences. These high density DNA micro-arrays will be and have been used to perform expression studies, re-sequencing experiments, and genotype analysis on the genes of human, mouse, and other organisms. The aforementioned genome oligo sets is a large set of unique 70 base pair nucleotides containing amine groups at their 5' ends. Operon has assembled a set of over 20,000 of these oligonucleotides for human genes and more than 16,000 for the mouse. These oligonucleotides will be used to construct high-density micro-arrays which will replace cDNA arrays now in use at the NCI. Operon is the only known company NCI believes that can offer large oligonucleotide sets of 70 bases (70 mers) in size that can be used for large scale expression studies. The NCI has significant experimental investment in array technologies and believes the Operon oligonucleotide are best suited to continue the experiment in progress without interruptions. This is not a request for competitive request. However, if any interested party believes it can meet the above requirement, it may submit a statement of capabilities. This statement must demonstrate that the oligonucleotides provided will be equivalent in quality and size, and encompass as many or more genes as the Operon set. The capability statement and any other furnished information must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can fully meet the requirement. Capability statements must be received in the contracting office by 1:00 PM EDT, (local Washington DC time) on July 26, 2002. If you have any questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at [email protected] or by fax at 301-402-4513. A determination by the Government not to compete this proposed requirement based on responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive requirement. No collect calls will be accepted. No faxed copies of capability statements will be accepted. Interested parties shall mail one original and two copies to: Malinda Holdcraft, NIH/NCI/RCB, 6120 Executive Blvd. Room 6072, Rockville, Maryland 20852-7194.

Bid Protests Not Available